Table 6.

Scenario analyses conducted to assess the cost effectiveness of molnupiravir

Scenario 1: Analysis applying MOVe-OUT subgroup characteristics and outcomes to all patients (tested for 10 subgroups: > 60 years of age; ≤ 60 years of age; BMI ≥ 30; BMI < 30; with diabetes; without diabetes; symptom onset to randomization ≤ 3 days; symptom onset to randomization >3 days (≤ 5 days); mild COVID-19 severity at baseline; moderate COVID-19 severity at baseline)

Scenario 2: Analysis using health state utility values from the published literature, rather than from de novo primary research

Scenario 3: Analysis not including long-term sequelae and readmission events

Scenario 4: Analysis using baseline risk data from US real-world data (TriNetX) rather than MOVe-OUT

Scenario 5: Analysis using baseline risk data from US real-world data rather than MOVe-OUT, and cost data from the Premier Health Database or published literature rather than TriNetX

Scenario 6: Societal perspective: analysis incorporating the societal impact of productivity losses among inpatients or symptomatic outpatients

Scenario 7: Variations of the above where vaccine effectiveness against hospitalization and mortality were varied

BMI body mass index, COVID-19 coronavirus disease 2019